Apr 23, 2025 8:05 am EDT Rezolute Announces Pricing of Offering of $90 Million of Common Stock and Pre-Funded Warrants
Apr 23, 2025 8:00 am EDT Rezolute Announces Positive Recommendation After Independent Interim Analysis of Phase 3 sunRIZE Study of Ersodetug in Congenital Hyperinsulinism (“HI”)
Mar 26, 2025 7:30 am EDT Rezolute Announces Appointment of Rare Disease Commercial Leader Erik Harris to its Board of Directors
Feb 12, 2025 4:05 pm EST Rezolute Reports Second Quarter Fiscal 2025 Financial Results and Provides Business Update
Feb 4, 2025 8:00 am EST Rezolute Provides Update on its Phase 3 sunRIZE Study of Ersodetug for the Treatment of Hypoglycemia Due to Congenital Hyperinsulinism
Jan 7, 2025 8:00 am EST Rezolute Receives Breakthrough Therapy Designation from FDA for Ersodetug in the Treatment of Hypoglycemia Due to Congenital Hyperinsulinism
Dec 3, 2024 8:00 am EST FDA Grants Orphan Drug Designation to Rezolute’s Ersodetug (RZ358) for the Treatment of Hypoglycemia Due to Tumor Hyperinsulinism
